(Alliance News) - Avacta Group PLC on Monday celebrated "rapid" progress on its joint venture in South Korea, following a second equity payment. Read More
(Alliance News) - Avacta Group PLC on Thursday said that it has bought Coris Bioconcept SRL, adding a range of professional-use rapid tests to its product portfolio. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - Avacta Group PLC on Thursday said it opened its first two clinical investigator sites for the phase 1 clinical trial of AVA6000 on Wednesday, under it US investigational new drug application. Read More
(Alliance News) - Avacta Group PLC on Wednesday said the first patient has been dosed in the fifth cohort of the first-in-human phase 1 trial of AVA6000, a novel form of doxorubicin designed to improve its safety and therapeutic index. Read More
(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Avacta Group PLC on Tuesday closed its GBP2.0 million open offer of shares, bringing its total fundraise to GBP64.0 million. Read More
(Alliance News) - Avacta Group PLC on Tuesday announced a GBP62.0 million fundraise, which will be partially used to finance its acquisition of Launch Diagnostics Holdings Ltd for up GBP37 million. Read More
(Alliance News) - Avacta Group PLC on Thursday reported a narrowed interim loss as it multiplied its revenue significantly thanks to a strong performance from its Therapeutics division. Read More
(Alliance News) - Avacta Group PLC said on Wednesday its candidate for multiple forms of cancer, AVA6000 Pro-doxorubicin, is advancing to its fourth dose cohort. Read More
(Alliance News) - Avacta Group PLC on Thursday said that its joint venture AffyXell with Daewoong Pharmaceuticals Co Ltd has successfully completed a funding round. Read More
(Alliance News) - Avacta Group PLC said on Thursday that LG Chem Life Sciences has exercised its renewal option as part of an ongoing collaboration with the company, triggering a fee payment of USD2 million to Avacta. Read More
(Alliance News) - Avacta Group PLC said on Wednesday its candidate for multiple forms of cancer, AVA6000 Pro-doxorubicin, is advancing to its third dose cohort after "a positive review of the safety data" from the second cohort. Read More
